Tvardi Therapeutics logo
Tvardi Therapeutics
TVRD | NASDAQ
Chart Builder DCF Calculator
$1.10
-$0.08 (-6.78%)
At close: Nov 16, 2026, 4:00 PM ET
$1.06
-$0.04 (-3.64%)
After-hours: Nov 16, 2026, 7:30 PM ET

Tvardi Therapeutics Company Profile

Company profile explained

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Key Executives

Name Position
Imran Alibhai Chief Executive Officer & Director
Dan Conn CFO & Corporate Secretary
David J. Tweardy Co-Founder & Scientific Advisory Board Member
Jeffrey Larson DABT Senior Vice President of R&D
John Kauh Chief Medical Officer
Michael T. Lewis Co-Founder & Scientific Advisory Board Member
Ronald A. DePinho Co-Founder & Chairman of Scientific Advisory Board
Stephen O'Brien Vice President of Finance & Corporate Controller
Yixin Chen Vice President of CMC

Latest SEC Filings

No SEC filings available
View All SEC Filings ➞
Tvardi Therapeutics
Tvardi Therapeutics logo
Country United States
IPO Date Jan 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Imran Alibhai

Contact Details

3 Sugar Creek Center Boulevard Sugar Land, Texas 77478 United States

Stock Details

Ticker Symbol TVRD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001346830
CUSIP Number 140755307
ISIN Number US1407553072
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.